Real-World Analysis of Persistence and Prescribing Patterns of TV-46000 for Schizophrenia Treatment
This research explores the prescribing patterns and characteristics of patients receiving the long-acting injectable (LAI) risperidone formulation TV-46000 for schizophrenia (SCZ) treatment in the US, showing high persistence rates and frequent use as a first-line treatment option.
TV-46000 can only be administered monthly or every 2 months. Researchers at AMCP Nexus 2024 aimed to analyze patient demographics, clinical details, and dosing frequencies for TV-46000 prescriptions in the US.
EVERSANA administrative claims data from August 2018 to February 2024 were analyzed for patients prescribed TV-46000. Patients with a minimum of 2 months of data before the index date or activity before May 1, 2023, were included. Persistence was calculated using Kaplan-Meier methodology based on time to discontinuation, defined as exceeding the fixed 30-day permissible gap. Line of therapy switching was studied for adult patients diagnosed with SCZ and treated with TV-46000.
Out of the 1773 patients treated with TV-46000, 715 had a diagnosis of SCZ. Among the 764 patients without an SCZ diagnosis, the majority had anxiety disorders, bipolar disorder, or schizoaffective disorder. The majority of patients did not switch between the 2 dosing frequencies, but of those who did, most switched from receiving the injection monthly to every 2 months.
A length of treatment analysis revealed that TV-46000 was commonly prescribed as the first or second-line SG LAI for patients with SCZ. Approximately 74% of adult patients with SCZ were persistent with TV-46000 treatment 4 months after the initial prescription.
“In the 10 months since approval, more than half of patients who received TV-46000 had started it as their first SG LAI. Persistence with TV-46000 was high, at 75% at 4 months,” said researchers.
Reference
Thompson S, Nathan R, Suett M, et al. Real-world TV-46000 prescribing behaviors in the United States since approval to treat schizophrenia: US claims database analysis of treatment patterns. Presented at: AMCP Nexus 2024; October 14-17; Las Vegas, NV.
